HUMAN PD-L2 TRIGGERS A UNIQUE T CELL INHIBITORY PROGRAM THROUGH PD-1 ENGAGEMENT DISTINCT FROM THAT OF PD-L1

被引：0
|
作者：
Srinivasamani, Anupallavi [1 ]
Curran, Michael [1 ]
Liu, Qinying [2 ]
Hegde, Shwetha [1 ]
Chen, Chao-Hsien [1 ]
Rajapakshe, Kimal [3 ]
Coarfa, Cristian
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Fudan Univ, Shanghai, Peoples R China
[3] Baylor Coll Med, Houston, TX 77030 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
233
引用
收藏
页码：A248 / A248
页数：1
相关论文
共 50 条
  • [21] Serum Level of PD-1, PD-L1, and PD-L2 as a New Biomarker for Esophageal Cancer
    Akutsu, Yasunori
    Murakami, Kentaro
    Hanari, Naoyuki
    Kano, Masayuki
    Uesato, Masaya
    Ota, Takumi
    Suito, Hiroshi
    Matsumoto, Yasunori
    Takahashi, Masahiko
    Matsubara, Hisahiro
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S694 - S694
  • [22] Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
    Javan, Mohammad Reza
    Aslani, Saeed
    Zamani, Mohammad Reza
    Rostamnejad, Javad
    Asadi, Milad
    Farhoodi, Mahdi
    Nicknam, Mohammad Hossein
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2016, 15 (04) : 296 - 302
  • [23] INTRAHEPATIC EXPRESSION OF PD-1, PD-L1 AND PD-L2 IN CHRONIC HEPATITIS B PATIENTS
    Chen, J.
    Lan, M. -D.
    Wu, X. -J.
    Zhao, J. -M.
    Lan, Z. -W.
    Wang, G-Q
    JOURNAL OF HEPATOLOGY, 2009, 50 : S205 - S205
  • [24] Association of PD-1, PD-L1 and PD-L2 expression with clinicopathological factors in tongue squamous cell carcinoma
    Tsuchihashi, Kei
    Nakatsugawa, Munehide
    Asanuma, Hiroko
    Miyazaki, Akihiro
    Torigoe, Toshihiko
    CANCER SCIENCE, 2018, 109 : 498 - 498
  • [25] DUAL-SPECIFIC ANTIBODIES BLOCKING BOTH PD-L1 AND PD-L2 ENGAGEMENT OF PD-1 RESTORE ANTITUMOR IMMUNITY
    Couillault, Coline
    Srinivasamani, Anupallavi
    Hedge, Shweta
    Liu, Qinying
    Jaiswal, Ashwin
    Zha, Dongxing
    Curran, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A315 - A315
  • [26] The PD-1 pathway in systemic lupus erythematosus: The Ligands of PD-1, PD-L1 and PD-L2, are also susceptibility factors.
    Abelson, AK
    Johansson, C
    Kozyrev, S
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S203 - S203
  • [27] PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma
    Stevenson, Valentina B.
    Perry, Samantha N.
    Todd, Michelle
    Huckle, William R.
    LeRoith, Tanya
    VETERINARY PATHOLOGY, 2021, 58 (04) : 692 - 698
  • [28] AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer
    Spirina, L. V.
    Avgustinovich, A. V.
    Afanas'ev, S. G.
    Kondakova, I. V.
    Volkov, M. Yu.
    Dobrodeev, A. Yu.
    Boronkina, A. I.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 170 (01) : 75 - 78
  • [29] Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
    Zak, Krzysztof M.
    Grudnik, Przemyslaw
    Magiera, Katarzyna
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    STRUCTURE, 2017, 25 (08) : 1163 - 1174
  • [30] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Jiang, Siqing
    Li, Xin
    Huang, Lihua
    Xu, Zhensheng
    Lin, Jinguan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345